Skip to Content

Physicians and Researchers Present at the American Association of Cancer Research Annual Meeting 2019

March 21, 2019

Physicians and Researchers Present at the American Association of Cancer Research Annual Meeting 2019.


UPMC Hillman Cancer Center physicians and researchers will be well-represented at the American Association of Cancer Research (AACR) Annual Meeting March 29 – April 3 in Atlanta, Ga. Faculty research will be featured in both oral presentations and poster sessions.


Saturday, March 30

Educational Sessions – 8 to 10 a.m.

Tumor Immunology and Immunotherapy for Nonimmunologists: Standard Cancer Therapies Are Ultimately Immunotherapies

Chair: Olivera J. Finn, Pittsburgh, PA

8:00 a.m. Chemotherapy converting to immunotherapy. Laurence Zitvogel, Villejuif, France

8:30 a.m. Radiotherapy as inducer of tumor immunity. Silvia C. Formenti, New York, NY

9:00 a.m. Virotherapy as inducer of antitumor immunity. Michael C. Brown, Durham, NC

9:30 a.m. Targeted therapy as ultimately immunotherapy. Ryan J. Sullivan, Boston, MA


Educational Sessions – 10:15 a.m. to 12:15 p.m.

Tumor Immunology and Immunotherapy for Nonimmunologists: Roundtable Discussions

Chair: Thomas F. Gajewski, Chicago, IL

Table 1: Turning cold tumors hot. Thomas F. Gajewski. Chicago, IL

Table 2: Cancer vaccines: Cancer immunoprevention. Olivera J. Finn, Pittsburgh, PA

Table 3: The microbiome in cancer. Laurence Zitvogel. Villejuif, France

Table 4: Combinations of radiotherapy with immunotherapy. Silvia C. Formenti, New York, NY

Table 5: Oncolytic viruses. Michael C. Brown, Durham, NC

Table 6: Immunotherapy toxicity. Ryan J. Sullivan, Boston, MA

Table 7: Immune checkpoint blockade in cancer therapy: Historical perspective, new opportunities, and prospects for cures. James P. Allison, Houston, TX

Table 8: Engineering T cells for tumor therapy. Philip D. Greenberg, Seattle, WA

Table 9: T-cell therapy. Patrick Hwu, Houston, TX Educational Sessions (cont’d) 08_canprog19_Sat_5.indd 72 3/4/19 5:16 PM PROGRAM GUIDE 73 SATURDAY

Table 10: CAR T cells. Carl H. June, Philadelphia, PA

Table 11: Biomarkers for response versus resistance. Jason J. Luke, Chicago, IL

Table 12: Advanced immunophenotyping of clinical samples. Alexander Swarbrick, Darlinghurst, Australia

Table 13: Translational biomarkers for cancer immunotherapy. Cornelia L. Trimble, Baltimore, MD

Table 14: Topic to be announced. Marc S. Ernstoff, Buffalo, NY

Table 15: Tumor-derived exosomes as biomarkers of cancer progression and reprogramming of the host immune system. Theresa L. Whiteside, Pittsburgh, PA


Sunday, March 31

Poster Sessions, 1 to 5 p.m.

Lifestyle Factors and Cancer Risk

Section 27, presentation number 631, poster board number 15

High BMI in relation to low risk of lung cancer among never smokers

Hung N. Luu, Renwei Wang, Jennifer Adams-Haduch, Aizhen Jin, Woon-Puay Koh, Jian-Min Yuan.


New Molecular Targets

Section 8, presentation number 199, poster board number 18

Therapeutic role of ESR1-CCDC170 gene fusion in breast cancer endocrine resistance

Li Li, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Ying Tan, Rachel Schiff, Xiaosong Wang.


Targeting Tumor-host Interactions

Section 27, presentation number 631, poster board number 15

TGF-β in exosomes facilitates HNSCC progression by accelerating tumor angiogenesis

Nils Ludwig, Saigopalakrishna S. Yerneni, Cynthia S. Hinck, Monika Pietrowska, Andrew P. Hinck, Theresa L. Whiteside.


Monday, April 1

Poster Sessions, 8 a.m. to noon

Immune Cells in the Tumor Microenvironment 1

Section 5, presentation number 1094, poster board number 17

Lipopolysaccharide-induced chronic inflammation promotes lung tumorigenesis in the context of an immunosuppressive microenvironment

Chia-Hsin Liu, Kong Chen, Yuanpu Di.


Convergence Science for Biomarkers, Early Detection, and Diagnosis

Section 30, presentation number 1642, poster board number 15

Spatial proteomics with hyperplexed fluorescence imaging predicts risk of colorectal cancer recurrence and infers recurrence-specific protein-protein networks

Shikhar Uttam, Andrew M. Stern, Samantha A. Furman, Filippo Pullara, Fiona Ginty, D. Lansing Taylor, S. Chakra Chennubhotla.


Innovative Concepts for Drug Discovery

Section 1, presentation number 993, poster board number 13

Chemotherapy enhances exosome secretion via upregulation of cholesterol metabolism in acute myeloid leukemia

Chang-Sook Hong, Emily J. Jeong, Beatrice Razzo, Michael Boyiadzis, Theresa L. Whiteside.


Major Symposia: 1 to 2:45 p.m.

Defining Systemic Tumor-Host Communication in Cancer Progression and Therapy Responses

Chair: Mikala Egeblad, Cold Spring Harbor, NY

1:05 p.m. Tumor-bone communications: Immune-suppressive effects of Dkk1. Roberta Faccio, St. Louis, MO

1:30 p.m. Neutrophils activated during inflammation drive metastasis and awakening of dormant disseminated cancer cells. Mikala Egeblad, Cold Spring Harbor, NY

1:55 p.m. Reprogramming tumor microenvironment metabolism to improve immunotherapy. Greg M. Delgoffe, Pittsburgh, PA

2:15 p.m. Improving immunotherapy efficacy by understanding mechanisms of resistance. Thomas F. Gajewski, Chicago, IL


Poster Sessions, 1 to 5 p.m.

Combination Immunotherapies 1

Section 19, presentation number 2257, poster board number 16


Phase II study of dual immune checkpoint blockade (ICB) with durvalumab (Durva) plus tremelimumab (T) following palliative hypofractionated radiotherapy (SBRT) in patients (pts) with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) progressing on chemotherapy: NSABP FC-9

James J. Lee, Greg Yothers, Thomas J. George, Marwan G. Fakih, Atrayee Basu Mallick, Edith P. Mitchell, James L. Wade, III, John C. Krauss, Omar R. Kayaleh, Dwight E. Heron, Carmen J. Allegra, Corey Lipchik, Huichen Feng, Marion Joy, Ashok Srinivasan, Katherine L. Pogue-Geile, Peter C. Lucas, Sarah E. Warren, Alessandra Cesano, Samuel A. Jacobs.


Oncogenic Transcription Factor Function

Section 37, presentation number 2604, poster board number 10

Constitutive activation of the human aryl hydrocarbon receptor in mice promotes hepatocarcinogenesis independent of its coactivator Gadd45b.

Peipei Lu, Xinran Cai, Zihui Fang, Wen Xie.


Novel Imaging Techniques

Section 5, presentation number 1942, poster board number 10

Volume and vascular evolution assessed with ultrasound in tumor growth: First steps for a future tool of predictive responses of treatment

Jerome Griffon, Zixin Yang, Delphine Le Guillou-Buffello, Alexandre Dizeux, Michele Lamuraglia, Lori Bridal.


Minisymposia 3 to 5 p.m.

Exposures and Genetics in Cancer Risk

Cochairs: Mia M. Gaudet, Atlanta, GA; Mariana C. Stern, Los Angeles, CA

3:00 p.m. Introduction

3:05 p.m. 2680   Intake of whole grain and dietary fiber and risk of hepatocellular carcinoma among U.S. adults. Wanshui Yang, Boston, MA

3:20 p.m. 2681   Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma. Jian-Min Yuan, Pittsburgh, PA

3:35 p.m. 2682   Analysis of polygenic risk score interaction with coal use and risk of lung adenocarcinoma among never-smoking women in Asia. Batel Blechter, Baltimore, MD

3:50 p.m. 2683   Biomarkers of glucose homeostasis and inflammation and risk of prostate cancer: A case-cohort study. Ying Wang, Atlanta, GA

4:05 p.m. 2684   Identification of 14 novel genetic loci for testicular germ cell tumor susceptibility. Louise C. Pyle, Philadelphia, PA

4:20 p.m. 2685   Identification of circulating protein biomarkers for colorectal cancer risk: A genetic instrument analysis. Xiang Shu, Nashville, TN

4:35 p.m. 2686   Associations between a polygenic risk score and risk of multiple myeloma and its precursor. Alyssa I. Clay-Gilmour, Rochester, MN


Tuesday, April 2

Poster Sessions, 8 a.m. to noon

Inflammation and Microbiome

Section 4, presentation number 2818, poster board number 4

Neutrophil extracellular traps regulate mitochondrial quality control in cancer cells to promote tumor growth

Samer Tohme, Hamza Yazdani, Richard L. Simmons, Allan Tsung, David Bartlett.


Tumor Radiosensitivity or Resistance

Section 8, presentation number 2919, poster board number 7

p16 modulates a novel ubiquitin signaling cascade which regulates radioresponse and offers clinically relevant therapeutic targets in squamous cell carcinoma

David Molkentine, Kathleen Bridges, Aakash Sheth, David Valdecanas, Curtis Pickering, Heath D. Skinner.


Immune Infiltration and Immune Therapy

Section 18, presentation number 3091, poster board number 1

Effects of melanoma cell-derived exosomes in melanoma patients’ plasma on immune cell functions

Priyanka Sharma, Brenda Diergaarde, Soldano Ferrone, John M. Kirkwood, Theresa L. Whiteside.


Tumor Radiosensitivity or Resistance

Section 8, presentation number 2925, poster board number 13

Targeting histone acetyltransferase (HAT) function for synthetic cytotoxicity in CREBBP/EP300 mutant tumors

Curtis Pickering, Manish Kumar, Kathleen Bridges, Tongxin Xie, David Molkentine, Aakash Sheth, Liang Yang, Mitchell Frederick, Tim Heffernan, Sahil Seth, Jeffrey Myers, Heath D. Skinner.


Applications of Cancer Computational Biology 1

Section 31, presentation number 3370, poster board number 1

Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers

Hatice Ulku Osmanbeyoglu, Fumiko Shimizu, Angela Rynne-Vidal, Tsz-Lun Yeung, Petar Jelinic, Samuel C. Mok, Gabriela Chiosis, Douglas A. Levine, Christina Leslie.


Tumor Radiosensitivity or Resistance

Section 8, presentation number 2913, poster board number 1

Serpinb3a-/- mice are radioresistant

Stephanie Thermozier, Michael Epperly, Darcy Franicola, Xichen Zhang, Renee Fisher, Donna Shields, Hong Wang, John Willis, Cliff Luke, Gary Silverman, Joel Greenberger.


Major Symposia – 1 to 2:45 p.m.

Advancing Epigenetic Therapies for Solid Tumors

Chair: Nancy E. Davidson, Seattle, WA

1:00 p.m. Introduction

1:05 p.m. Epigenetic therapies in GI cancers: Where do we go next? Nita Ahuja, New Haven, CT

1:35 p.m. Epigenetic therapies in lung cancer: Early excitement to current approaches. James G. Herman, Pittsburgh, PA

2:05 p.m. Prospects for epigenetic therapy for breast cancer. Nancy E. Davidson, Seattle, WA


Poster Sessions, 1 to 5 p.m.

Immunomodulation by Chemotherapy and Targeted Agents

Section 18, presentation number 3963, poster board number 19

Deep serial analysis of the TCR/BCR CDR3 adaptome repertoire in peripheral blood of pancreatic cancer patients in a randomized study of neoadjuvant chemotherapy with or without autophagy inhibition

Yue Wang, Michael T. Lotze.


Clinical Trials Minisymposium 3 – 3 to 5 p.m.

Developmental Therapeutics: Clinical Results of Novel Agents

Chair: Anthony El-Khoueiry, Los Angeles, CA

CT232 Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors. Khanh T. Do, Boston, MA

CT233 Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium phase II trial. Amy E. Armstrong, Indianapolis, IN

CT234 A phase II, single-arm study of maintenance rucaparib in patients with platinumsensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2, or PALB2. Kim A. Reiss Binder, Philadelphia, PA

CT235 A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. Kyle C. Cuneo, Ann Arbor, MI

CT236 Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster. Olivera J. Finn, Pittsburgh, PA

CT237 Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel. Rakesh Awasthi, East Hanover, NJ CT238 TAS-120 in patients with advanced solid tumors bearing FGF/FGFR aberrations: A phase I study. Funda Meric-Bernstam, Houston, TX


Minisymposia 3 to 5 p.m.

Genomic Correlates of Therapy Response

Cochairs: Anthony G. Letai, Boston, MA; Andrew J. Aguirre, Boston, MA

3:00 p.m. Introduction 3:05 p.m. 4472   The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma. Wen-Hsuan Yang, Durham, NC

3:20 p.m. 4473   DNMT and PARP inhibitor combination therapy induces an interferondriven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia. Lena J. McLaughlin, Baltimore, MD

3:35 p.m. 4474   Novel neoplastic RAD51AP1-DYRK4 fusion transcript in aggressive luminal breast cancers. Chia Chia Liu, Pittsburgh, PA

3:50 p.m. 4475   Targeting c-MET and MAPK pathway in metastatic castrationresistant prostate cancer. María Dolores Fenor de la Maza, Madrid, Spain

4:05 p.m. 4476   Therapeutic exploitation of passenger amplifications in hepatocellular carcinoma. Christos Patsis, Heidelberg, Germany

4:20 p.m. 4477   MIK665/S64315, a novel Mcl-1 inhibitor, in combination with Bcl-2 inhibitors exhibits strong synergistic antitumor activity in a range of hematologic malignancies. Youzhen Wang, Cambridge, MA (not eligible for CME credit)

4:35 p.m. 4478   High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors. Patrick D. Bhola, Boston, MA


Wednesday, April 3

Poster Sessions, 8 a.m. to noon

Cancer Chemoprevention and Interception: From Mechanism to Translation

Section 27, presentation number 5081, poster board number 19

Leelamine is a novel inhibitor of fatty acid synthesis in prostate cancer

Krishna B. Singh, Shivendra V. Singh.


Cellular and Stromal Interactions of Tumor Cells

Section 33, presentation number 5155, poster board number 7

Increased longevity of continuous bone marrow cultures and radioresistance of bone marrow stromal cells from SOD193A ALS (Amyotrophic Lateral Sclerosis) mice

Andrew Henderson, Michael W. Epperly, Renee Fisher, Donna Shields, Lora Rigatti, Christopher Donnelly, Simon Watkins, Joel S. Greenberger.


Tumor Evolution and Heterogeneity 3

Section 9, presentation number 4702, poster board number 15

Characterization of ultrasound and immunohistochemichal parameters during development of murine tumor

Jerome Griffon, Delphine Le Guillou-Buffello, Lori Bridal, Michele Lamuraglia.


Influences on Cancer Risk and Outcomes

Section 26, presentation number 5059, poster board number 23

Early life risk factors and childhood cancer risk

Shaina L. Stacy, Jeanine M. Buchanich, Zhen-qiang Ma, Christina Mair, Linda Robertson, Ravi K. Sharma, Evelyn O. Talbott, Jian-Min Yuan.